Skip navigation.

Consolidated Guidelines On Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations For A Public Health Approach (2nd Edition)

Corporate author: 
World Health Organisation (WHO)
Publication details: 
Geneva, WHO, 2016

These guidelines provide guidance on the diagnosis of human immunodeficiency virus
(HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, treatment and care. They include several new recommendations, including the recommendation to provide lifelong ART to all children, adolescents and adults, including all pregnant and breastfeeding women living with HIV, regardless of CD4 cell count. WHO has also expanded earlier recommendations to offer PrEP to selected people at substantial risk of acquiring HIV. Alternative first-line treatment regimens are recommended, including an
integrase inhibitor as an option in resource-limited settings and reduced dosage of a key recommended first-line drug, efavirenz, to improve tolerability and reduce costs. Because of their anticipated public health impact, the new recommendations on when to start ART and the use of PrEP contained in these guidelines were released in September 2015.